By Michael Smith, North American Correspondent, MedPage Today
Published: November 10, 2011
SAN FRANCISCO -- After years with a standard two-drug therapy for the hepatitis C virus (HCV), new agents that act directly on the virus are making an appearance, with two already approved. And at the annual meeting of the American Association for the Study of Liver Diseases, details are being reported on many more in the pipeline.
In this exclusive InFocus segment, MedPage Today North American Correspondent Michael Smith sat down to discuss the new agents with Gary Davis, MD, of Baylor University Medical School in Dallas
No comments:
Post a Comment